Gene mutation affects his Mo Xifen to treat the successful rate of breast cancer

German investigator says, the gene CYP2D6 of encode P450 and CYP2C19 mutation can forecast the success that uses his Mo Xifen to treat estrogen to get body positive breast cancer to perhaps fail.

Investigator of 　 　 Germany says, the gene CYP2D6 of encode P450 and CYP2C19 mutation can forecast the success that uses his Mo Xifen to treat estrogen to get body positive breast cancer to perhaps fail. Germany Dr. HiltrudBrauch of clinical pharmacodynamics institute says Situjiate: "The clinical importance of this kind of discovery is to pass genotype to be able to find him Mo Xifen treats may effective patient, still those need replace remedial patient, one needs the result with large and clinical certain trial. One needs the result with large and clinical certain trial..

　 　 will publish on November 20 " clinical oncology magazine " (JournalofClinicalOncology) go up, dr. Brauch and its work in the same placing detected 206 patients that accept his Mo Xifen to assist cure and 280 genotype DNA of the patient that did not accept treatment.

Photograph of the person that wait for a gene to carry compares discovery of 　 　 investigator and functional sex, he not has CYP2D6 to wait for a gene *4, *5, *10 and *41 mutation in group of Xi Fen treatment (fight estrogen metabolization content to form reduce concerned gene) patient, lift apparently with rate of breast cancer recrudesce about, they return those who discover these patients to shorten without recrudescent duration, and the survival rate that do not have disease is reduced.

　　 in addition, wait for a gene with CYP2C19 1, 2, photograph of the 3 person that carry is compared, carry high enzymatic active to promote child the 17 patients that wait for a gene mutation are clinical curative effect is better.

　 　 Dr. Brauch says, these discovery conduce to refute to medication the concept of all diseases, according to genotype much model the gender chooses endocrine treatment. As a result of immanent character, can to differring diagnostic material of other of the Zhou Xiehe outside the patient of disease period undertakes genotype detect. This kind detects can be in the most inchoate will medication individual change, bring the profit of the oldest rate to the patient.